Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured Whitepaper
Key Success Factors to Building a Best Practice Medical Affairs Organization
Learn More >
Featured Whitepaper
Building Peak Performance Go-to-Market Operations: Capturing the Value of Medical Innovation in a Fast-Changing Landscape
Learn More >
Blog
Portfolio Forecasting (Part 1): Finding the Optimum Approach to Portfolio Valuation
Whitepaper
How Science Can Drive Better Business Decisions in Biopharma
Blog
Highlights of EULAR 2025: Progress in Complex Rheumatological Diseases and Implications for the Future Landscape
Blog
Some Key Takeaways from ASCO 2025
Whitepaper
UK Biotech Club Recap (May 2025) – Navigating Transatlantic Headwinds: Assessing the Impact of U.S. Policy on the Growth of UK Biotech
Blog
Guidance for Evaluating MFN: Part 3 – Key Considerations for Deals
Blog
Autoimmune and Inflammatory Diseases in Women: Unmet Needs and Opportunities for Biopharma Companies
Blog
Guidance for Evaluating MFN: Part 2 – Impact on Pharma Channel Partner and Customer Business
Blog
ISPOR 2025: A Brief Recap
Whitepaper
Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank
Blog
Guidance for Evaluating MFN: Part 1 – Key Questions for Biopharma Manufacturers
Blog
How Science Can Drive Better Business Decisions in Biopharma Part 2: Applying a Decision-Making Framework
Blog
The American Academy of Neurology Annual Meeting, 2025: A Recap of Key Themes
Whitepaper
Key Success Factors to Building a Best Practice Medical Affairs Organization
Whitepaper
The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC
Blog
Thoughts from the MAPS 2025 Americas Meeting
